A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pidnarulex (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man

25 Aug 2021 According to a Senhwa Biosciences media release, the company announced the initiation of dose escalation portion of the study.
12 Dec 2017 Results (n=16) assessing maximum tolerated dose (MTD), safety, pharmacokinetic (PK) profile and antitumor activity, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
29 May 2015 Interim results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com